Search results

  1. J

    Trial Report Plasma cell targeting with the anti-CD38 antibody daratumumab in ME/CFS -a clinical pilot study, 2025, Fluge et al

    Makes one wonder if Multiple Myeloma patients could get away with fewer injections as well?? I’m guessing they want to be really really sure that they wipe out all the LLPCs in this case.
  2. J

    Trial Report Plasma cell targeting with the anti-CD38 antibody daratumumab in ME/CFS -a clinical pilot study, 2025, Fluge et al

    I’m assuming that they didn’t go with this revised protocol for the full Phase 2 study because they didn’t want to take the risk that weren’t fully depleting LLPC’s. With this very small sub-sample they could take the risk of doing fewer injections. FWIW, this is very different from the...
  3. J

    Trial Report Plasma cell targeting with the anti-CD38 antibody daratumumab in ME/CFS -a clinical pilot study, 2025, Fluge et al

    Here is the revised PILOT protocol. “Protocol ver. 1.6: Amended treatment protocol; this will apply to four additional patients included in Q1 2025, as well as retreatment of one previously included patient with partial relapse. Patients will receive the first daratumumab subcutaneous injection...
  4. J

    Invivyd and Leading Researchers Form SPEAR Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID

    Two out of the three individuals mentioned here have no expertise in the “clinical and translational biology of LC and PVS”.
  5. J

    Invivyd - monoclonal antibodies

    Mind if I ask how you were prescribed this medication? Isn’t it indicated for immunocompromised people as a Covid prophylaxis or treatment?
  6. J

    Elevated risk of new-onset chronic fatigue syndrome/myalgic encephalomyelitis up to four years after SARS-CoV-2 infection 2025 Hadidchi et al.

    Background Fatigue is a common sequela of SARS-CoV-2 infection, with many COVID-19 patients subsequently developing chronic fatigue syndrome and myalgic encephalomyelitis (CFS/ME). Long-term associations between COVID-19, new-onset CFS/ME, and other independent predictors such as vaccination for...
  7. J

    Invivyd - monoclonal antibodies

    Merged Scientist Dr Akiko Iwasaki joins SPEAR study group to investigate monoclonal antibodies for Long Covid and Covid-19 post-vaccination syndrome Press release—does anyone think this will work...
  8. J

    The Dangers of Crowdsourced 'Cures' for Long COVID—Medpage

    If anyone has interest/energy, if you sign up for a Medpage account, you can comment on the article. FWIW, I had no idea this guy was that bad when I posted.
  9. J

    Ozempic, tirzepatide and other GLP-1RAs - impact on ME/CFS

    If GLP-1 Drugs Are Good For Everything, Should We All Be on Them? https://www.derekthompson.org/p/why-does-it-seem-like-glp-1-drugs?utm_campaign=post&utm_medium=web
  10. J

    The Dangers of Crowdsourced 'Cures' for Long COVID—Medpage

    https://www.medpagetoday.com/opinion/second-opinions/116618 Of course, a simple Google search turns up the doc who wrote this opinion piece treats Long Covid related mitochondrial dysfunction with graded exercise therapy.
  11. J

    Hypothesis Hypothesis: A Mechanical Basis: Brainstem Dysfunction as a Potential Etiology of ME/CFS and Long COVID, 2025, Jeff Wood, Kaufman et al.

    OK, trying to sort this out. Jeff’s affiliation on the paper is Renegade Research, which is a nonprofit. His email on the paper is jeff@mech*nicalbasis.org. He is listed on the Chiari EDS Center website, which doesn’t look like a nonprofit, with an email for the Mount Sinai hospital system...
  12. J

    Long Covid drug BC-007 research news

    A rare drug trial for long Covid failed, yielding lessons on study design BC 007, a German infusion that had lifted hope of patients, is heading for new study https://www.statnews.com/2025/07/22/long-covid-research-mistakes-to-fix/
  13. J

    Hamsters with long COVID present distinct transcriptomic profiles associated with neurodegenerative processes in brainstem 2025 Coleon et al.

    Following infection with SARS-CoV-2, patients may experience with one or more symptoms that appear or persist over time. Neurological symptoms associated with long COVID include anxiety, depression, and memory impairment. However, the exact underlying mechanisms are not yet fully understood...
  14. J

    Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review 2025 Kattamuri et al.

    Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of various hematological malignancies. Recently, CAR-T has been used in refractory auto-immune diseases with initial encouraging results. In this systematic review, we examined the safety and efficacy of CAR-T in...
  15. J

    Trial Report Plasma cell targeting with the anti-CD38 antibody daratumumab in ME/CFS -a clinical pilot study, 2025, Fluge et al

    Cort Johnson article. In the comments there is one MECFS patient on Dara for MM, with no beneficial effects on MECFS symptoms. https://www.healthrising.org/blog/2025/07/18/b-cell-depleter-long-covid-daratumumab-chronic-fatigue/ ETA Cort highlights IgG4 because he has high IgG4.
  16. J

    Chronic Lyme Disease Was Once Dismissed. More Doctors Are Coming Around.

    https://www.wsj.com/health/chronic-lyme-disease-ticks-treatment-f075b588 Mentions “Long Covid” and fibromyalgia but of course not MECFS. Meh.
  17. J

    I Teach Creative Writing. This Is What A.I. Is Doing to Students.—-Meghan O’Rourke (mentions chronic illness)

    Essay by Invisible Kingdom Author Meghan O’Rouke “But in other aspects of life, A.I. surprised me. I asked it to write memos, draft job postings, create editorial checklists — even offer its opinion on the order of poems in an anthology I was assembling. Tasks I might otherwise have avoided or...
  18. J

    Accelerating biomedical discoveries in brain health through transformative neuropathology of aging and neurodegeneration, 2025, Murray et al.

    Summary Transformative neuropathology is redefining human brain research by integrating foundational descriptive pathology with advanced methodologies. These approaches, spanning multi-omics studies and machine learning applications, will drive discovery for the identification of biomarkers...
Back
Top